 Growth differentiation factor-8 |
| The present invention provides a cell growth and differentiation factor, GDF-8, a polynucleotide ... |
|
| Staphylococcus antigen and vaccine |
| It is therefore an object of the present invention to provide an antigen common to a majority of ... |
|
| Antigenic compositions and methods for using same |
| We claim: 1. An antigenic conjugate which is immunoreactive with anti-GM2 antibodies produced by ... |
|
| Stress proteins and uses therefor |
| The present invention relates to stress proteins and methods of modulating an individual's (such as ... |
|
| Methods for using heat shock proteins |
| OF THE PREFERRED EMBODIMENT Definitions For the purposes of the present invention, the term "toxin"... |
|
| Induction of a Th1-like response in vitro |
| The invention is based on the discovery that a cell sample containing naive lymphocytes can be ... |
|
| Method for producing cell-fushion type morbillivirus mutants |
| What is claimed is: 1. A method for reducing the cell-fusion ability of a virus comprising ... |
|
| Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
| An object of the present invention is to provide a method for enhancing the immunogenicity of an ... |
|
| Cationic oligopeptides having microbicidal activity |
| What is claimed is: 1. A method for inhibiting microbial growth in an environment susceptible to ... |
|
|
Vaccine against mumps containing a jeryl-lynn virus strain
| Details |
Inventors: Harford, Nigel Maurice; Colau, Brigitte Desiree Alberte; Didelez, Jean;
Assignee: SmithKline Beecham Biologicals, s.a. (Rixensart, BE)
Primary Examiner: Housel; James
Assistant Examiner: McGraw; Michael
Attorney, Agent or Firm: Majarian; William R., Fedon; Jason C., Gimmi; Edward R.
A new mumps vaccine is presented, comprising a homogeneous pure isolate derived from the Jeryl-Lynn strain of mumps virus. In a preferred embodiment of the invention the vaccine produces higher seroconversion and anitbody titres than know commercial vaccines. |
|
DETAILED DESCRIPTION 1.
A combined vaccine comprising a substantially homogeneous immunogenic Jeryl-Lynn isolate, an attenuated measles virus, an attenuated rubella virus, and an agent for protection against varicella zoster infection, the vaccine not contaminated with more than 10% of another Jeryl-Lynn isolate.
2.
A combined vaccine comprising a substantially homogeneous immunogenic Jeryl-Lynn isolate, a killed measles virus, a killed rubella virus, and an agent for protection against varicella zoster infection, the vaccine not contaminated with more than 10% of another Jeryl-Lynn isolate.
3.
A combined vaccine comprising a substantially homogeneous immunogenic Jeryl-Lynn isolate, a subunit of a measles virus, a subunit of a rubella virus, and an agent for protection against varicella zoster infection, the vaccine not contaminated with more than 10% of another Jeryl-Lynn isolate.
4.
A method of inducing immunity in a mammal to measles, mumps, rubella and varicella zoster virus infections comprising administration to the mammal of an effective amount of a vaccine according to claim 1.
5.
A method of inducing immunity in a mammal to measles, mumps, rubella and varicella zoster virus infections comprising administration to the mammal of an effective amount of a vaccine according to claim 2.
6.
A method of inducing immunity in a mammal to measles, mumps, rubella and varicella zoster virus infections comprising administration to the mammal of an effective amount of a vaccine according to claim 3.
Description:
Mumps is essentially a disease of childhood, which normally presents itself with only minor symptoms.
However, in certain cases the clinical consequences of mumps infection are serious.
For example, mumps is the most common cause of meningoencephalitis in children under 15 years of age in the UK, and a cause of permanent sensorineural deafness in childhood.
Although 30-40% of natural mumps infection are symptomless, the very fact that salivary gland involvement can be unpleasant and that in the adult population mumps can cause 1st trimester abortions and orchitis of men as well as the neurological complications noted above, has led, in many countries, to the adoption of mass vaccination programs
|
| Related patents |
|
|
DNA sequences which encode immunoreactive HCMV-specific peptides
We claim: 1. An isolated and purified DNA fragment consisting of HCMV DNA sequence, wherein said HCMV DNA sequence is contained within the DNA encoding amino acids 718-88...
|
|
|
Vaccines absorbable by the transmucosal way
OF THE INVENTION The Applicants observed that when antigens, also of proteic nature, are coated with polysaccharides, they are absorbed by the mucosa and stimulate both ...
|
|
|
Method of detecting mycoplasma infection in poultry and compositions therefor
OF THE INVENTION As used herein, the term "antigen" refers to a protein, polypeptide, or Coomassie blue staining band purified by the method described below and ...
|
|
|
FcεPE chimeric protein for targeted treatment of allergy responses, a method for its production and pharmaceutical compositions containing the same
OF THE INVENTION The Fc-PE chimeric protein according to the present invention has a number of advantages over the existing known drugs.: 1. Specificity: Fc-PE is ...
|
|
|
Targeting of dosages of medicine and therapeutic agents
The embodiments of the invention from which an exclusive property of privilege is claimed are as follows: 1. A method of treating a disease or condition in a human ...
|
|
|
Method of delivering a protein to poultry
In accordance with the present invention, it has been discovered that a protein can be administered to domestic birds by whole-body spraying of the birds with an ...
|
|
|
Attenuated recombinant rabies virus mutants and live vaccines thereof
OF THE INVENTION Preferred mutants according to the invention may be obtained by deleting residues 143 to 149 or 139 to 149 of the phosphoprotein (P) of rabies virus ...
|
|
|
Modified forms of Hepatitis C NS3 protease for facilitating inhibitor screening and structural studies of protease: inhibitor complexes
OF THE INVENTION The benefit of this invention is that the modified forms of HCV NS3 protease retain full activity, yet are highly amenable to biochemical ...
|
|
|
Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
In its broadest aspect, the present invention is directed to a monoclonal antibody, or binding fragment thereof, which specifically binds to antigens sharing a common ...
|
|
|
Recombinant infectious laryngotracheitis virus and uses thereof
OF THE INVENTION The present invention provides a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains ...
|
|
|
Drugs 
